Pharmacology Research & Perspectives
译名:药理学研究与展望
1-3
2026
影响因子区间
—
平台估算
15%
2025
中国作者发文占比
2433 GBP
收费
期刊简介:PR&P is jointly published by the American Society for Pharmacology and Experimental Therapeutics (ASPET), the British Pharmacological Society (BPS), and Wiley. PR&P is a bi-monthly open access journal that publishes a range of article types, including: target validation (preclinical papers that show a hypothesis is incorrect or papers on drugs that have failed in early clinical development); drug discovery reviews (strategy, hypotheses, and data resulting in a successful therapeutic drug); frontiers in translational medicine (drug and target validation for an unmet therapeutic need); pharmacological hypotheses (reviews that are oriented to inform a novel hypothesis); and replication studies (work that refutes key findings [failed replication] and work that validates key findings). PR&P publishes papers submitted directly to the journal and those referred from the journals of ASPET and the BPS
【译文】PR&P是由美国药理学与实验治疗学会(ASPET)、英国药理学学会(BPS)和威利出版社共同出版的期刊。PR&P是一本双月刊开放获取期刊,发表多种类型的文章,包括:靶点验证(显示假设错误的临床前论文或早期临床试验失败的药物论文);药物发现综述(策略、假设和数据,导致成功治疗药物);转化医学前沿(针对未满足的治疗需求的药物和靶点验证);药理学假设(旨在提供新假设的综述);以及复制研究(反驳关键发现[失败复制]和验证关键发现的工作)。PR&P发表直接提交给期刊的论文以及从ASPET和BPS的期刊转来的论文

| 指标 | 当前值 | 近三年趋势 |
|---|---|---|
| JCR分区 | Q3 | 暂无 |
| 中科院分区 | 4区 | 暂无 |
| 影响因子区间 | 1-3 | 暂无 |